GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook

About this update from Genedx Holdings Corp.

GAITHERSBURG, Md., May 04, 2026--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026. "GeneDx delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that there’s sustained, strong demand for our services. While our revenue did not reflect the full potential of what this business is capable of, we are adjusting our outlook and are poised to deliver more than 30% volume growth, 70% gross margin, and profitability on an adjusted basis for the year," said Katherine Stueland, CEO of GeneDx. "Leading a generational shift in medicine requires taking some big swings, learning quickly, and moving with urgency to serve this ever-growing patient population. With expectations reset, we’ve never been more confident about our ability to deliver profitable growth in service of patients and shareholders." First Quarter 2026 Financial Results (Unaudited)(1) Revenue Exome and genome volume Gross margin Operating expenses Net (loss) income Cash position Updated 2026 Guidance GeneDx has updated its 2026 guidance. Management now expects GeneDx to deliver: First Quarter 2026 and Recent Business Highlights Strategic Expansion and Market Leadership Innovation & Clinical Leadership Webcast and Conference Call Details GeneDx will host a conference call today, May 4, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. Non-GAAP Financial Measures GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and sh...

View stock analysis, news, and events for Genedx Holdings Corp.